Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib eye drops in treatment-naive neovascular age-related macular degeneration
2012-003763-22Phase 2Terminated
- Sponsor
- Bayer
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of regorafenib in exudative macular degeneration (3 arms), sponsored by Bayer. Primary endpoint: Mean change in visual acuity. Started May 2014; status: terminated.
02
Drugs
regorafenib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2012-003763-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003763-22.